The value of animal models in the development of new drugs for the treatment of the sepsis syndrome
Author:
Open Access
- 1 January 1998
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 41 (suppl 1) , 47-49
Abstract
The sepsis syndrome has proved to be one of the most difficult clinical situations to replicate in animal models. The outcome of sepsis in patients depends not only on the pathogens, sizes of bacterial challenge and adequacy of treatment, but also on age, host defence mechanisms and individual response to septic shock and multiple organ failure. Novel immunomodulatory agents may control endotoxaemia or bacteraemia in animal models but they have not proved effective in septic patients. This article considers whether the principal problem lies in our interpretation of the data from animal studies, or whether such models are unsuitable for assessing new treatments for the sepsis syndrome.Keywords
This publication has 4 references indexed in Scilit:
- Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis.The Journal of Immunology, 1990
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice.Journal of Experimental Medicine, 1987
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985